ESG206 for adults with hard-to-treat ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been diagnosed with primary immune thrombocytopenia (ITP).
- You should have tried standard treatments like steroids or IVIG, and they didn't work well or caused problems.
- Your platelet count must be under 30,000 twice (on two separate tests at least 24 hours apart).
- You cannot have other causes of low platelets, like certain other immune disorders or cancers.
- You must not have had specific treatments (like rituximab) or a splenectomy in the past 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
This study tests a new injection called SG301-SC for people with primary immune thrombocytopenia (ITP) whose platelet counts stay low even after standard treatments. The goal is to see if it is safe and helps raise platelets, reducing bleeding risk.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.